2National Comprehensive Cancer Network. NCCN clinical practiceguidelines in oncology: cancer and chemotherapy-induced anemia.2011, V. 2 [EB/OL]. (2011-08-01). http://www. nccn. org/index. asp.
3Del Mastro L, Gennari A, Donati S. Chemotherapy of non-small-celllung cancer: role of erythropoietin in the management of anemia[J].Ann Oncol, 1999,10 (Suppl 5): 91-94.
4Ludwig H, Van Belle S, Barrett-Lee P, et al. The European CancerAnaemia Survey (ECAS): A large, multinational, prospective surveydefining the prevalence; incidence, and treatment of anaemia in cancerpatients [J]. EurJ Cancer, 2004,40: 2293-2306.
5Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietinresponse in patients with the anemia of cancer[j]. N EngJ Med, 1990,322: 1689-1692.
6Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical,biologic, and molecular aspects[J].J Natl Cancer Inst, 2001, 93: 266-276.
7Ludwig H, Fritz E. Anemia in cancer patients [J]. Semin Oncol,1998,25 (3 Suppl 7):2-6.
8Leyland-Jones B, Semiglazov V,Pawlicki M, et al. Maintaining normalhemoglobin levels with epoetin alfa in mainly nonanemic patients withmetastatic breast cancer receiving first-line chemotherapy: A survivalstudy[J].J Clin Oncol, 2005,23(25): 5960-5972.
9Bohlius J, Schmidlin K, Brillant C, et al. Recombinant humanerythropoiesis-stimulating agents and mortality in patients with cancer:a meta-analysis of randomised trials [J]. Lancet, 2009,373: 1532-1542.
10Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individualpatient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin-alfa in the treatment of patients withchemotherapy-induced anemia[J].J Clin Oncol, 2009, 27:2838-2847.
